Effectiveness of Coenzyme Q10 Supplementation for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Objective. To evaluate the effectiveness and safety of coenzyme Q10 for patients with type 2 diabetes mellitus (T2DM). Methods. Data from randomized controlled trials were obtained to assess the effects of coenzyme Q10 versus placebo or western medicine on patients with T2DM. The study’s registratio...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2018/6484839 |
id |
doaj-c2ab151f743d49c2a208c0ea29b2a942 |
---|---|
record_format |
Article |
spelling |
doaj-c2ab151f743d49c2a208c0ea29b2a9422020-11-25T00:05:00ZengHindawi LimitedInternational Journal of Endocrinology1687-83371687-83452018-01-01201810.1155/2018/64848396484839Effectiveness of Coenzyme Q10 Supplementation for Type 2 Diabetes Mellitus: A Systematic Review and Meta-AnalysisShi-ying Zhang0Kai-lin Yang1Liu-ting Zeng2Xiao-he Wu3Hui-yong Huang4Hunan University of Chinese Medicine, Changsha 410208, ChinaHunan University of Chinese Medicine, Changsha 410208, ChinaHunan University of Chinese Medicine, Changsha 410208, ChinaJiangxi Provincial People’s Hospital, Nanchang 330006, ChinaHunan University of Chinese Medicine, Changsha 410208, ChinaObjective. To evaluate the effectiveness and safety of coenzyme Q10 for patients with type 2 diabetes mellitus (T2DM). Methods. Data from randomized controlled trials were obtained to assess the effects of coenzyme Q10 versus placebo or western medicine on patients with T2DM. The study’s registration number is CRD42018088474. The primary outcomes included glycosylated hemoglobin, fasting blood glucose, and fasting insulin. Result. Thirteen trials involving 765 patients were included. Compared with the control group, coenzyme Q10 may decrease the HbA1c (WMD −0.29; 95% CI −0.54, −0.03; P=0.03) and the fasting blood glucose (WMD −11.21; 95% CI −18.99, −3.43; P=0.005). For fasting insulin, there is also not strong evidence that confirms which one is better because there was no statistical difference (WMD −0.48; 95% CI −2.54, 1.57; P=0.65). Conclusion. Based on current evidence, coenzyme Q10 may assist glycemic control, decrease TG, and improve HDL-C in patients with T2DM.http://dx.doi.org/10.1155/2018/6484839 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shi-ying Zhang Kai-lin Yang Liu-ting Zeng Xiao-he Wu Hui-yong Huang |
spellingShingle |
Shi-ying Zhang Kai-lin Yang Liu-ting Zeng Xiao-he Wu Hui-yong Huang Effectiveness of Coenzyme Q10 Supplementation for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis International Journal of Endocrinology |
author_facet |
Shi-ying Zhang Kai-lin Yang Liu-ting Zeng Xiao-he Wu Hui-yong Huang |
author_sort |
Shi-ying Zhang |
title |
Effectiveness of Coenzyme Q10 Supplementation for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis |
title_short |
Effectiveness of Coenzyme Q10 Supplementation for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis |
title_full |
Effectiveness of Coenzyme Q10 Supplementation for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis |
title_fullStr |
Effectiveness of Coenzyme Q10 Supplementation for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis |
title_full_unstemmed |
Effectiveness of Coenzyme Q10 Supplementation for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis |
title_sort |
effectiveness of coenzyme q10 supplementation for type 2 diabetes mellitus: a systematic review and meta-analysis |
publisher |
Hindawi Limited |
series |
International Journal of Endocrinology |
issn |
1687-8337 1687-8345 |
publishDate |
2018-01-01 |
description |
Objective. To evaluate the effectiveness and safety of coenzyme Q10 for patients with type 2 diabetes mellitus (T2DM). Methods. Data from randomized controlled trials were obtained to assess the effects of coenzyme Q10 versus placebo or western medicine on patients with T2DM. The study’s registration number is CRD42018088474. The primary outcomes included glycosylated hemoglobin, fasting blood glucose, and fasting insulin. Result. Thirteen trials involving 765 patients were included. Compared with the control group, coenzyme Q10 may decrease the HbA1c (WMD −0.29; 95% CI −0.54, −0.03; P=0.03) and the fasting blood glucose (WMD −11.21; 95% CI −18.99, −3.43; P=0.005). For fasting insulin, there is also not strong evidence that confirms which one is better because there was no statistical difference (WMD −0.48; 95% CI −2.54, 1.57; P=0.65). Conclusion. Based on current evidence, coenzyme Q10 may assist glycemic control, decrease TG, and improve HDL-C in patients with T2DM. |
url |
http://dx.doi.org/10.1155/2018/6484839 |
work_keys_str_mv |
AT shiyingzhang effectivenessofcoenzymeq10supplementationfortype2diabetesmellitusasystematicreviewandmetaanalysis AT kailinyang effectivenessofcoenzymeq10supplementationfortype2diabetesmellitusasystematicreviewandmetaanalysis AT liutingzeng effectivenessofcoenzymeq10supplementationfortype2diabetesmellitusasystematicreviewandmetaanalysis AT xiaohewu effectivenessofcoenzymeq10supplementationfortype2diabetesmellitusasystematicreviewandmetaanalysis AT huiyonghuang effectivenessofcoenzymeq10supplementationfortype2diabetesmellitusasystematicreviewandmetaanalysis |
_version_ |
1725426798349516800 |